The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target

被引：45

作者：

Yamada, Y ^{[1
]}

Pannell, R ^{[1
]}

Forster, A ^{[1
]}

Rabbitts, TH ^{[1
]}

机构：

[1] Med Res Council Lab Mol Biol, Cambridge CB2 2QH, England

来源：

ONCOGENE | 2002年 / 21卷 / 09期

关键词：

transcriptional regulation; tumour angiogenesis; chromosomal translocation; endothelium; cancer; neo-vascularization;

D O I：

10.1038/sj.onc.1205285

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LM02 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional significance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LM02 function may be a drug target in cancer and other conditions characterized by neo-vascularization.

引用

页码：1309 / 1315

页数：7

共 23 条

[1] THE RHOMBOTIN FAMILY OF CYSTEINE-RICH LIM-DOMAIN ONCOGENES - DISTINCT MEMBERS ARE INVOLVED IN T-CELL TRANSLOCATIONS TO HUMAN CHROMOSOME-11P15 AND CHROMOSOME-11P13 [J].

BOEHM, T ;

FORONI, L ;

KANEKO, Y ;

PERUTZ, MF ;

RABBITTS, TH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4367-4371

[2] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[3] Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood [J].

Chang, YS ;

di Tomaso, E ;

McDonald, DM ;

Jones, R ;

Jain, RK ;

Munn, LL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (26) :14608-14613

[4] Clinical applications of angiogenic growth factors and their inhibitors [J].

Ferrara, N ;

Alitalo, K .

NATURE MEDICINE, 1999, 5 (12) :1359-1364

[5]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[6] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].

FOLKMAN, J .

NATURE MEDICINE, 1995, 1 (01) :27-31

[7] ANTI-ANGIOGENESIS - NEW CONCEPT FOR THERAPY OF SOLID TUMORS [J].

FOLKMAN, J .

ANNALS OF SURGERY, 1972, 175 (03) :409-&

[8] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].

Hanahan, D ;

Folkman, J .

CELL, 1996, 86 (03) :353-364

[9] SPONTANEOUS AND CARCINOGEN-INDUCED TUMORIGENESIS IN P53-DEFICIENT MICE [J].

HARVEY, M ;

MCARTHUR, MJ ;

MONTGOMERY, CA ;

BUTEL, JS ;

BRADLEY, A ;

DONEHOWER, LA .

NATURE GENETICS, 1993, 5 (03) :225-229

[10] LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes [J].

Rabbitts, TH .

GENES & DEVELOPMENT, 1998, 12 (17) :2651-2657

← 1 2 3 →